Pleural Effusion in Dasatinib-Treated Patients With Chronic Myeloid Leukemia in Chronic Phase: Identification and Management

被引：63

作者：

Cortes, Jorge E. ^{[1
]}

Jimenez, Carlos A. ^{[2
]}

Mauro, Michael J. ^{[3
]}

Geyer, Alex ^{[4
]}

Pinilla-Ibarz, Javier ^{[5
]}

Smith, B. Douglas ^{[6
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, 1515 Holcombe Blvd,Unit 0428, Houston, TX 77030 USA

[2] Univ Texas MD Anderson Canc Ctr, Dept Pulm Med, Houston, TX 77030 USA

[3] Mem Sloan Kettering Canc Ctr, Myeloproliferat Neoplasms Program, 1275 York Ave, New York, NY 10021 USA

[4] Mem Sloan Kettering Canc Ctr, Pulm Serv, 1275 York Ave, New York, NY 10021 USA

[5] H Lee Moffitt Canc Ctr & Res Inst, Malignant Oncol Div, Tampa, FL USA

[6] Johns Hopkins Sidney Kimmel Comprehens Canc, Dept Oncol, Baltimore, MD USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2017年 / 17卷 / 02期

关键词：

Adverse events; Algorithms; BCR-ABL1; Fluid retention; Tyrosine kinase inhibitor; ADVERSE EVENTS; IMATINIB; RECOMMENDATIONS; THERAPY; CT;

D O I：

10.1016/j.clml.2016.09.012

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Dasatinib has demonstrated durable clinical responses in patients, both as first-line and subsequent lines of therapy. Dasatinib use can result in pleural effusion in some patients, occurring any time during treatment and commonly characterized as mild to moderate in severity. Early identification of symptoms is essential in the proper management of pleural effusion. Prompt confirmation of diagnosis and management of pleural effusion can minimize morbidity and maximize the ability to preserve long-term clinical benefits with dasatinib. Here, we provide guidance on early identification and management of dasatinib-related pleural effusion.

引用

页码：78 / 82

页数：5

共 50 条

[11] Clinical significance of dasatinib-induced pleural effusion in patients with de novo chronic myeloid leukemia
Nakaya, Aya
Fujita, Shinya
Satake, Atsushi
Nakanishi, Takahisa
Azuma, Yoshiko
Tsubokura, Yukie
Hotta, Masaaki
Yoshimura, Hideaki
Ishii, Kazuyoshi
Ito, Tomoki
Nomura, Shosaku
HEMATOLOGY REPORTS, 2018, 10 (03) : 65 - 68
[12] Recurrence of pleural effusion on bosutinib therapy in a dasatinib treated patient with chronic myeloid leukaemia
Milojkovic, D.
Zaiga-Castleton, A.
Marin, D.
Reid, A.
Foroni, L.
Rezvani, K.
Bua, M.
Khorashad, J.
Goldman, J.
Apperley, J.
BRITISH JOURNAL OF HAEMATOLOGY, 2010, 149 : 83 - 83
[13] Bosutinib - related pleural effusion in patients with chronic myeloid leukemia
Yuzbasioglu, Mebrure Burcak
Eskazan, Ahmet Emre
EXPERT OPINION ON DRUG SAFETY, 2021, 20 (04) : 379 - 381
[14] NK-Cells In Dasatinib-Treated Chronic Myeloid Leukemia Patients Display a Unique Phenotype Associated With Cytotoxic Potential
Fernandez, Beatriz Colom
Kreutzman, Anna
Garcia, Valentin
Requena Rodriguez, Maria Jose
Mascunano, Raul Cordoba
Gutierrez, Begona Maestro
Steegmann, Juan Luis
Calleja, Cecilia Munoz
BLOOD, 2013, 122 (21)
[15] Long-Term Results and Characteristics of Pleural Effusion in Late Chronic Phase Chronic Myeloid Leukemia Patients at Dasatinib Therapy after Imatinib Failure
Gusarova, Galina
Bykova, Anastasia
Vorontsova, Alexandra
Kuznetsov, Sergey
Shukhov, Oleg
Chelysheva, Ekaterina
Lazareva, Olga
Goryacheva, Svetlana
Ivanova, Tatyana
Turkina, Anna G.
BLOOD, 2015, 126 (23)
[16] Exacerbation of pleural effusion in a dasatinib-treated patient during the perioperative period
Hasegawa, Takayuki
Inoue, Satoki
Yoshida, Keisuke
Akatsu, Masahiko
JA CLINICAL REPORTS, 2022, 8 (01)
[17] PLEURAL EFFUSION IN DASATINIB-TREATED CML PATIENTS: INCIDENCE AND MANAGEMENT IN A REAL-LIFE ITALIAN MULTICENTER SERIES
Iurlo, A.
Galimberti, S.
Abruzzese, E.
Annunziata, M.
Bonifacio, M.
Latagliata, R.
Pregno, P.
Ferrero, D.
Sora, F.
Orlandi, E.
Fava, C.
Cattaneo, D.
Bucelli, C.
Binotto, G.
Pioltelli, M. L.
Tiribelli, M.
Gozzini, A.
Gugliotta, G.
Castagnetti, F.
Stagno, F.
Rege-Cambrin, G.
Martino, B.
Luciano, L.
Consonni, D.
Breccia, M.
Sica, S.
Bocchia, M.
Rosti, G.
Specchia, G.
Cortelezzi, A.
HAEMATOLOGICA, 2017, 102 : 83 - 84
[18] Analysis of patients (pts) with chronic phase chronic myeloid leukemia (CML-CP) who develop pleural effusion on first-line dasatinib: Management and outcomes.
Laneuville, P.
Baccarani, M.
Cortes, J. E.
Hochhaus, A.
Kantarjian, H.
Shah, N. P.
Bradley-Garelik, M. B.
Zhu, C.
Porkka, K.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[19] Association of Pleural Effusion and Bleeding in Patients with Chronic Myelogenous Leukemia Receiving Dasatinib
Qufntas-Cardama, Alfonso
Kantarjian, Hagop M.
O'Brien, Susan
Ravandi, Farhad
Ferrajoli, Alessandra
Garcia-Manero, Guillermo
Cortes, Jorge
BLOOD, 2008, 112 (11) : 735 - 735
[20] Exacerbation of pleural effusion in a dasatinib-treated patient during the perioperative period
Takayuki Hasegawa
Satoki Inoue
Keisuke Yoshida
Masahiko Akatsu
JA Clinical Reports, 8

← 1 2 3 4 5 →